Advertisement

Importance of serum glycoside concentrations

  • K. Kochsiek
Conference paper

Abstract

For drug-mediated therapy it was a great advance when dose-related response could be replaced by correlating blood level and effect. The various factors, which related to the dose could influence the blood level, the concentration at the site of effect and finally the intensity of effect, are shown in Table 1. From this synopsis it could be deduced that for digitalis glycosides some of these factors are well-known. The absorption rate of digitoxin is 100%, for digoxin 80% and more. It is not advisable to administer drugs with a lower absorption rate. The distribution volume is also known. For the closely protein-bound digitoxin (protein binding 92–97%), it is about 0.5–0.71/kg body weight and for digoxin with a protein binding of 25% about 6–101/kg body weight, thus for a patient of 70 kg body weight resulting in a distribution volume for digitoxin of 51 and for digoxin of about 500–6001 respectively. Even metabolic passage and speed of elimination are well known. While digitoxin with a half-life of approximately 200 hours is mainly metabolized, digoxin is almost totally excreted via the kidney. In contrast, the significance and quantitative extent of those factors which are able to influence the concentration of glycosides at the site of action are far less known. Best studied and documented by empirical observations is the importance of pathological conditions on the intensity of effect. Here the synergism of hypokalemia and hypercalcemia and vice versa should be mentioned. The increased sensitivity for glycosides in hypoxemia is well known, especially in cor pulmonale as well as in prolonged severe heart failure, but also in hypothyroidism.

Keywords

Atrial Tachycardia Digitalis Glycoside Cardiac Side Effect Glycoside Concentration Pacemaker Patient 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Arnim Th v, Krawietz W, Vogt W, Erdmann E (1980) Is the determination of serum digoxin concentration useful for the diagnosis of digitalis toxicity? Int J Clin Pharmacol Ther Toxicol 18: 261 – 268Google Scholar
  2. 2.
    Beller GA, Smith TW, Abelman WH, Haber E, Hood WB Jr (1971) Digitalis intoxication: A prospective clinical study with serum level correlations. New Engl J Med 284: 989Google Scholar
  3. 3.
    Binnion PF, Morgan LM, Stevenson HM (1969) Plasma and myocardial digoxin concentrations in patients on oral therapy. Brit Heart J 31: 636PubMedCrossRefGoogle Scholar
  4. 4.
    Coltart J, Howard M, Chamberlain D (1972) Myocardial and skeletal muscle concentrations of digoxin in patients on long-term therapy. Br Med J 2: 318PubMedCrossRefGoogle Scholar
  5. 5.
    Doering W, König E (1978) Anstieg der Digoxinkonzentration im Serum unter Chinidinmedikation. Med Klin 73: 1085PubMedGoogle Scholar
  6. 6.
    Doherty JE, Perkins WH, Flanigan WH (1967) The distribution and concentration of tritiated digoxin in human tissues. Ann Intern Med 66: 116PubMedCrossRefGoogle Scholar
  7. 7.
    Erdmann E (1981) Influence of cardiac glycosides on their receptor. In: Greeff K (ed) Handbook of Experimental Pharmacology, Vol 56. Springer-Verlag Berlin Heidelberg New York, pp 337 – 380Google Scholar
  8. 8.
    Fogelman A, Finkelstein MS, La Monte JT, Rado E, Pearce ML (1971) Fallibillity of plasma digoxin in differentiating toxic from nontoxic patients. Lancet i: 727Google Scholar
  9. 9.
    Greeff K, Strobach H, Verspohl E (1975) Ergebnisse radioimmunologischer Bestimmungen von Digitoxin, Digoxin und g-Strophanthin am Menschen. In: Jahrmärker H (Hrsg) Digitalistherapie. Springer-Verlag, Berlin Heidelberg New York, p 52Google Scholar
  10. 10.
    Haasis R, Larbig D, Stunkat R, Bader H, Seboldt H (1977) Radioimmunologische Bestimmung der Glykosidkonzentration im menschlichen Gewebe. Klin Wschr 55: 23PubMedCrossRefGoogle Scholar
  11. 11.
    Haasis R, Larbig D, Decot M, Futter G (1977) Zur Glykosidtherapie bei Schrittmacherpatienten. Verh Dtsch Ges Inn Med 83: 1653PubMedGoogle Scholar
  12. 12.
    Ingelfinger JA, Goldman P (1976) The serum digitalis concentration — does it diagnose digitalis toxicity? New Engl J Med 294: 867PubMedCrossRefGoogle Scholar
  13. 13.
    Jahrmärker H (1975) Probleme der Digitalisintoxikation. In: Jahrmärker H (Ed) Digitalistherapie. Springer-Verlag, Berlin Heidelberg New York, p 80Google Scholar
  14. 14.
    Kochsiek K, Larbig D, Haasis R (1977) Klinik und Therapie der Digitalisintoxikation. Verh Dtsch Ges Inn Med 83: 99 – 115PubMedGoogle Scholar
  15. 15.
    Koch-Weser J (1972) Serum drug concentrations as therapeutic guides. New Engl J Med 287: 227PubMedCrossRefGoogle Scholar
  16. 16.
    Koch-Weser J (1974) Biovailability of drugs. New Engl J Med 291: 233 – 503Google Scholar
  17. 17.
    Larbig D, Haasis R, Kochsiek K (1977) Die Glykosidkonzentration und ihre klinische Bedeutung. Forum cardiologicum 15, Boehringer Mannheim, 1 – 138Google Scholar
  18. 18.
    Lasagna L (1976) How useful are serum digitalis measurements. New Engt J Med 294: 890 – 899Google Scholar
  19. 19.
    Paumgartner G (1976) Die Serumkonzentration von Digitalisglykosiden als therapeutische Richtlinie. Schweiz Med Wschr 106: 909PubMedGoogle Scholar
  20. 20.
    Ochs HR, Greenblatt DJ, Harmatz JS, Bodem G, Dengler HJ (1981) Clinical implications of serum digoxin concentrations. Klin Wochenschr 59: 501 – 507PubMedCrossRefGoogle Scholar
  21. 21.
    Smith TW, Butler VP, Haber E (1969) Determination of therapeutic and toxic serum digoxin concentrations by radio-immunoassay. New Engl J Med 281: 1212PubMedCrossRefGoogle Scholar
  22. 23.
    Smith TW, Haber E (1970) Digoxin intoxication: The relationship of clinical presentation to serum di-goxin concentration. J Clin Invest 49: 2377Google Scholar
  23. 24.
    Smith TW, Haber E (1971) The clinical value of serum digitalis glycoside concentrations in the evaluation of drug toxicity. Ann N Y Acad Sci 179: 322PubMedCrossRefGoogle Scholar
  24. 25.
    Schatzmann HJ (1953) Herzglykoside als Hemmstoffe für den aktiven Kalium-und Natriumtransport durch die Erythrocytenmembran. Hely Physiol Acta 11: 346 – 354Google Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1986

Authors and Affiliations

  • K. Kochsiek
    • 1
  1. 1.LuitpoldkrankenhausMedizinische Universitäts KlinikWürzburgWest Germany

Personalised recommendations